Authors also comment that although the study identified some evidence that the proportional effect of SGLT2 inhibitors might attenuate with declining kidney function (p for trend=0·073), there was clear, separate evidence of benefit for all eGFR subgroups, including for participants with a baseline eGFR 30–45 mL/min per 1.73 m2 (RR 0.70, 95% CI 0.54–0.91, p=0.0080). Renoprotection was consistent across studies irrespective of baseline albuminuria (p for trend=0·66) and use of reno-angiotensin-system blockade (p for heterogeneity=0.31).